Buy SpaceX Stock on Day 1 -- But Only if You Can Answer These 3 Questions

The article argues SpaceX’s IPO is likely to face extreme volatility and potential underperformance, despite bullish buzz around the listing. It cites 2024 revenue of $18.7 billion, $8.6 billion of growth spending, and a valuation above 90 times last year’s revenue, implying the stock may be difficult to justify at the IPO/open-market price. The piece emphasizes insider share-sale overhangs at 70, 90, 105, 120, and 135 days post-listing and warns investors to scrutinize fundamentals before chasing an IPO pop.

Analysis

The first-order setup is not “IPO upside,” it is a volatility supply event. A high-profile listing with a staged insider release schedule creates a path-dependent trade: early strength can mechanically set up future distribution, while any post-deal weakness can compound because there is no natural buyback support in the first 3-5 months. That means the real tradeable edge is likely in options market structure and in timing around unlock windows, not in chasing day-one momentum.

Second-order beneficiaries are the public-market comparables that can absorb enthusiasm without the same lockup overhang. NDAQ may get a modest sentiment lift from renewed IPO attention, but the bigger effect is on capital allocation within tech: money rotating into a headline-grabbing pre-profitability asset is typically financed by selling higher-quality liquid growth names, which can create temporary relative-value dislocations in NFLX, NVDA, and even INTC. The article’s emphasis on revenue scale versus valuation also underscores how hard it will be for the market to justify multiple expansion unless there is a visible acceleration in monetization, not just engineering progress.

The contrarian point is that the market may be underpricing how quickly enthusiasm can reverse once the first two quarterly prints force a reality check. The best historical analog is not a moonshot tech debut; it is a liquidity event that becomes a sentiment barometer for the entire private-market complex. If the stock opens above implied fundamentals, the asymmetry shifts toward faded multiple compression over the next 60-180 days, especially as insider sale dates approach and early holders look to de-risk into strength.

A more subtle risk is that public investors anchor on the headline market size while ignoring execution bottlenecks and capital intensity. If operating leverage fails to materialize, the stock can remain expensive for months yet still underperform materially on a 1-year basis, which makes outright long exposure a poor risk/reward unless paired with a defined catalyst and a strict exit plan.

Key Decisions for Investors

• Avoid chasing the IPO on day 1; if forced to express a view, use a 1-3 month put spread or put ratio spread after the opening volatility settles, targeting the first post-lockup drawdown window as insiders begin to gain sell access.
• Pair trade: long NDAQ / short the new listing into the first 90 days. NDAQ benefits from renewed issuance activity and trading volumes, while the new stock faces lockup overhang and valuation compression risk.
• Tactically trim or hedge NVDA and NFLX on strength if the IPO pop drives broad growth-factor inflows. Use this as a short-duration relative-value rotation trade, not a structural bearish call.
• If the stock stays above deal price for 2-4 weeks, sell upside calls against any long exposure; implied volatility should remain rich, and call overwriting monetizes the event premium while capping upside in a crowded narrative trade.
• Set a calendar alert for the 70/90/105-day insider release windows; if the shares are still extended into those dates, initiate or add to a short on evidence of elevated borrow availability and weakening post-earnings momentum.